Stockreport
Is Evotec SE (EVO) One of the Best Debt-Free Penny Stocks to Buy Right Now? [Yahoo! Finance]
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
Biologics received a new grant from the Gates Foundation. The grant is to be used to enable global access to the company's biotherapeutics utilizing Evotec Biologics' molecular design suite. Copyright: nexusplexus / 123RF Stock Photo The Gates Foundation grant is also part of an effort to improve the development and reduce the cost of monoclonal antibodies. The ultimate goal is to make them affordable and accessible to prevent infectious disease in low and middle-income countries. The grant comes on the heels of reports that Evotec is poised to benefit from Amgen's Dark Blue Acquisition. As one of the early collaborators and investors in Oxford-based Dark Blue, the company is entitled to some proceeds from the transaction. The transaction carries a potential value of up to $840 million. Evotec has been involved in the development and expansion of Dark Blue's technology platform and holds an equity stake of about 20%. “Evotec welcomes Amgen's acquisition of Dark Blue Therapeuti
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | AMGN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
AMGN alerts
AMGN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
NEWS
NEWS
- Nonprofit Health Services Organization Files Lawsuit Against Fortune 500 Pharmaceutical Company Over Prescription Drug Access[Business Wire]
- Amgen (NASDAQ:AMGN) was downgraded by analysts at Sanford C. Bernstein from an "outperform" rating to a "market perform" rating. They now have a $335.00 price target on the stock.[MarketBeat]
- Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Results? [Yahoo! Finance][Yahoo! Finance]
- Kaléo Strengthens Leadership Team to Advance Drug Delivery and Autoinjector Innovation [Yahoo! Finance][Yahoo! Finance]
- Amgen Inc. (NASDAQ:AMGN) is largely controlled by institutional shareholders who own 80% of the company [Yahoo! Finance][Yahoo! Finance]
- More
AMGN
SEC Filings
SEC Filings
- 11/21/25 - Form 4
- 11/20/25 - Form 144
- 11/13/25 - Form 4
- AMGN's page on the SEC website
- More